Qiagen has been among the most aggressive acquirers in the multi-platform molecular biology tools space. The firm has made six acquisitions since April, with a particular focus on proteomics and molecular diagnostic applications. This week, Qiagen CEO Peer Schatz spoke with BioCommerce Week about the firm's rapidly expanding portfolio and its acquisition strategy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.